Properdin: a tightly regulated critical inflammatory modulator

Immunological Reviews

Volumn 274, Issue 1, 2016, Pages 172-190

  Blatt, Adam Z ^a   Pathan, Sabina ^a   Ferreira, Viviana P ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

complement; factor H; inflammation; properdin

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CD40 LIGAND; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR ANTAGONIST; COMPLEMENT FACTOR H; COMPLEMENT MEMBRANE ATTACK COMPLEX; DIMER; ECULIZUMAB; FIBRINOGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; INTERCELLULAR ADHESION MOLECULE 2; MONOMER; OLIGOMER; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; PENTRAXIN 3; PROPERDIN; TETRAMER; THROMBOSPONDIN; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1;

CARBOXY TERMINAL SEQUENCE; CELL AGGREGATION; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT INHIBITION; COMPLEMENT LECTIN PATHWAY; GRANULOCYTE; HUMAN; INFLAMMATION; INNATE IMMUNITY; NEUTROPHIL; NONHUMAN; OLIGOMERIZATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; THROMBOCYTE; THROMBOCYTE ACTIVATION; ANIMAL; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; MOLECULARLY TARGETED THERAPY; THROMBOCYTE AGGREGATION; THROMBOSIS;

ANIMALS; COMPLEMENT FACTOR H; COMPLEMENT PATHWAY, ALTERNATIVE; HUMANS; IMMUNOMODULATION; INFLAMMATION; MOLECULAR TARGETED THERAPY; PLATELET AGGREGATION; PROPERDIN; THROMBOSIS;

EID: 84992460231     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12466     Document Type: Review

References (213)

1. Holers VM. Complement and its receptors: new insights into human disease. Annu Rev Immunol. 2014;32:433–459.
2. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I – molecular mechanisms of activation and regulation. Front Immunol. 2015;6:262.
3. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785–797.
4. Klos A, Tenner AJ, Johswich KO, Ager RR, Reis ES, Kohl J. The role of the anaphylatoxins in health and disease. Mol Immunol. 2009;46:2753–2766.
5. Morgan BP. The membrane attack complex as an inflammatory trigger. Immunobiology. 2016;221:747–751.
6. Hamad OA, Mitroulis I, Fromell K, et al. Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18. Thromb Haemost. 2015;114:1207–1217.
7. Nilsson B, Nilsson Ekdahl K. The tick-over theory revisited: is C3 a contact-activated protein? Immunobiology. 2012;217:1106–1110.
8. Pangburn MK, Muller-Eberhard HJ. Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med. 1980;152:1102–1114.
9. Isenman DE, Kells DI, Cooper NR, Muller-Eberhard HJ, Pangburn MK. Nucleophilic modification of human complement protein C3: correlation of conformational changes with acquisition of C3b-like functional properties. Biochemistry. 1981;20:4458–4467.
10. Fishelson Z, Pangburn MK, Muller-Eberhard HJ. Characterization of the initial C3 convertase of the alternative pathway of human complement. J Immunol. 1984;132:1430–1434.
11. Mullereberhard HJ, Dalmasso AP, Calcott MA. The reaction mechanism of beta-1C-globulin (C'3) in immune hemolysis. J Exp Med. 1966;123:33–54.
12. Fearon DT, Austen KF, Ruddy S. Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. J Exp Med. 1973;138:1305–1313.
13. Pangburn MK, Schreiber RD, Muller-Eberhard HJ. C3b deposition during activation of the alternative complement pathway and the effect of deposition on the activating surface. J Immunol. 1983;131:1930–1935.
14. Harboe M, Ulvund G, Vien L, Fung M, Mollnes TE. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol. 2004;138:439–446.
15. Harboe M, Garred P, Karlstrom E, Lindstad JK, Stahl GL, Mollnes TE. The down-stream effects of mannan-induced lectin complement pathway activation depend quantitatively on alternative pathway amplification. Mol Immunol. 2009;47:373–380.
16. Ferreira VP, Pangburn MK, Cortes C. Complement control protein factor H: the good, the bad, and the inadequate. Mol Immunol. 2010;47:2187–2197.
17. Weiler JM, Daha MR, Austen KF, Fearon DT. Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci USA. 1976;73:3268–3272.
18. Whaley K, Ruddy S. Modulation of the alternative complement pathways by beta 1 H globulin. J Exp Med. 1976;144:1147–1163.
19. Pangburn MK, Schreiber RD, Muller-Eberhard HJ. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med. 1977;146:257–270.
20. Esparza-Gordillo J, Soria JM, Buil A, et al. Genetic and environmental factors influencing the human factor H plasma levels. Immunogenetics. 2004;56:77–82.
21. Gordon DL, Kaufman RM, Blackmore TK, Kwong J, Lublin DM. Identification of complement regulatory domains in human factor H. J Immunol. 1995;155:348–356.
22. Kuhn S, Skerka C, Zipfel PF. Mapping of the complement regulatory domains in the human factor H-like protein 1 and in factor H1. J Immunol. 1995;155:5663–5670.
23. Kuhn S, Zipfel PF. Mapping of the domains required for decay acceleration activity of the human factor H-like protein 1 and factor H. Eur J Immunol. 1996;26:2383–2387.
24. Ferreira VP, Herbert AP, Hocking HG, Barlow PN, Pangburn MK. Critical role of the C-terminal domains of factor H in regulating complement activation at cell surfaces. J Immunol. 2006;177:6308–6316.
25. Ferreira VP, Pangburn MK. Factor H mediated cell surface protection from complement is critical for the survival of PNH erythrocytes. Blood. 2007;110:2190–2192.
26. Jokiranta TS, Cheng ZZ, Seeberger H, et al. Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site. Am J Pathol. 2005;167:1173–1181.
27. Jozsi M, Oppermann M, Lambris JD, Zipfel PF. The C-terminus of complement factor H is essential for host cell protection. Mol Immunol. 2007;44:2697–2706.
28. Losse J, Zipfel PF, Jozsi M. Factor H and factor H-related protein 1 bind to human neutrophils via complement receptor 3, mediate attachment to Candida albicans, and enhance neutrophil antimicrobial activity. J Immunol. 2010;184:912–921.
29. Pangburn MK. Cutting edge: localization of the host recognition functions of complement factor H at the carboxyl-terminal: implications for hemolytic uremic syndrome. J Immunol. 2002;169:4702–4706.
30. Pickering MC, de Jorge EG, Martinez-Barricarte R, et al. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med. 2007;204:1249–1256.
31. Saggu G, Cortes C, Emch HN, Ramirez G, Worth RG, Ferreira VP. Identification of a novel mode of complement activation on stimulated platelets mediated by properdin and C3(H2O). J Immunol. 2013;190:6457–6467.
32. Sanchez-Corral P, Perez-Caballero D, Huarte O, et al. Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. Am J Hum Genet. 2002;71:1285–1295.
33. Stahl AL, Vaziri-Sani F, Heinen S, et al. Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood. 2008;111:5307–5315.
34. Vaziri-Sani F, Hellwage J, Zipfel PF, Sjoholm AG, Iancu R, Karpman D. Factor H binds to washed human platelets. J Thromb Haemost. 2005;3:154–162.
35. Pickering MC, Cook HT, Warren J, et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet. 2002;31:424–428.
36. Ruseva MM, Vernon KA, Lesher AM, et al. Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency. J Am Soc Nephrol. 2013;24:43–52.
37. de Cordoba SR, de Jorge EG. Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol. 2008;151:1–13.
38. Ferreira VP, Herbert AP, Cortes C, et al. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol. 2009;182:7009–7018.
39. Herbert AP, Uhrin D, Lyon M, Pangburn MK, Barlow PN. Disease-associated sequence variations congregate in a polyanion recognition patch on human factor H revealed in three-dimensional structure. J Biol Chem. 2006;281:16512–16520.
40. Jokiranta TS, Jaakola VP, Lehtinen MJ, Parepalo M, Meri S, Goldman A. Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome. EMBO J. 2006;25:1784–1794.
41. Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol. 2013;33:508–530.
42. Lehtinen MJ, Rops AL, Isenman DE, van der Vlag J, Jokiranta TS. Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome. J Biol Chem. 2009;284:15650–15658.
43. Perez-Caballero D, Gonzalez-Rubio C, Gallardo ME, et al. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet. 2001;68:478–484.
44. Perkins SJ, Goodship TH. Molecular modelling of the C-terminal domains of factor H of human complement: a correlation between haemolytic uraemic syndrome and a predicted heparin binding site. J Mol Biol. 2002;316:217–224.
45. Banda NK, Mehta G, Ferreira VP, et al. Essential role of surface-bound complement factor H in controlling immune complex-induced arthritis. J Immunol. 2013;190:3560–3569.
46. Renner B, Klawitter J, Goldberg R, et al. Cyclosporine induces endothelial cell release of complement-activating microparticles. J Am Soc Nephrol. 2013;24:1849–1862.
47. Takeda K, Thurman JM, Tomlinson S, et al. The critical role of complement alternative pathway regulator factor H in allergen-induced airway hyperresponsiveness and inflammation. J Immunol. 2012;188:661–667.
48. Renner B, Ferreira VP, Cortes C, et al. Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury. Kidney Int. 2011;80:165–173.
49. Lesher AM, Zhou L, Kimura Y, et al. Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis. J Am Soc Nephrol. 2013;24:53–65.
50. Loeven MA, Rops AL, Lehtinen MJ, et al. Mutations in complement factor H impair alternative pathway regulation on mouse glomerular endothelial cells in vitro. J Biol Chem. 2016;291:4974–4981.
51. Hyvarinen S, Meri S, Jokiranta TS. Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome. Blood. 2016;127:2701–2710.
52. Pangburn MK, Muller-Eberhard HJ. The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase. Biochem J. 1986;235:723–730.
53. Fearon DT, Austen KF. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med. 1975;142:856–863.
54. Alcorlo M, Tortajada A, Rodriguez de Cordoba S, Llorca O. Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin. Proc Natl Acad Sci USA. 2013;110:13504–13509.
55. Farries TC, Lachmann PJ, Harrison RA. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products. Biochem J. 1988;252:47–54.
56. Farries TC, Lachmann PJ, Harrison RA. Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement. Biochem J. 1988;253:667–675.
57. Medicus RG, Gotze O, Muller-Eberhard HJ. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J Exp Med. 1976;144:1076–1093.
58. Nolan KF, Reid KB. Complete primary structure of human properdin: a positive regulator of the alternative pathway of the serum complement system. Biochem Soc Trans. 1990;18:1161–1162.
59. Sun Z, Reid KB, Perkins SJ. The dimeric and trimeric solution structures of the multidomain complement protein properdin by X-ray scattering, analytical ultracentrifugation and constrained modelling. J Mol Biol. 2004;343:1327–1343.
60. Smith CA, Pangburn MK, Vogel CW, Muller-Eberhard HJ. Molecular architecture of human properdin, a positive regulator of the alternative pathway of complement. J Biol Chem. 1984;259:4582–4588.
61. Smith KF, Nolan KF, Reid KB, Perkins SJ. Neutron and X-ray scattering studies on the human complement protein properdin provide an analysis of the thrombospondin repeat. Biochemistry. 1991;30:8000–8008.
62. Higgins JM, Wiedemann H, Timpl R, Reid KB. Characterization of mutant forms of recombinant human properdin lacking single thrombospondin type I repeats. Identification of modules important for function. J Immunol. 1995;155:5777–5785.
63. Hartmann S, Hofsteenge J. Properdin, the positive regulator of complement, is highly C-mannosylated. J Biol Chem. 2000;275:28569–28574.
64. Holt GD, Pangburn MK, Ginsburg V. Properdin binds to sulfatide [Gal(3-SO4)beta 1-1 Cer] and has a sequence homology with other proteins that bind sulfated glycoconjugates. J Biol Chem. 1990;265:2852–2855.
65. Pangburn MK. Analysis of the natural polymeric forms of human properdin and their functions in complement activation. J Immunol. 1989;142:202–207.
66. Perdikoulis MV, Kishore U, Reid KB. Expression and characterisation of the thrombospondin type I repeats of human properdin. Biochim Biophys Acta. 2001;1548:265–277.
67. Bertram P, Akk AM, Zhou HF, Mitchell LM, Pham CT, Hourcade DE. Anti-mouse properdin TSR 5/6 monoclonal antibodies block complement alternative pathway-dependent pathogenesis. Monoclon Antib Immunodiagn Immunother. 2015;34:1–6.
68. Fredrikson GN, Westberg J, Kuijper EJ, et al. Molecular characterization of properdin deficiency type III: dysfunction produced by a single point mutation in exon 9 of the structural gene causing a tyrosine to aspartic acid interchange. J Immunol. 1996;157:3666–3671.
69. Fijen CA, van den Bogaard R, Schipper M, et al. Properdin deficiency: molecular basis and disease association. Mol Immunol. 1999;36:863–867.
70. Fredrikson GN, Gullstrand B, Westberg J, Sjoholm AG, Uhlen M, Truedsson L. Expression of properdin in complete and incomplete deficiency: normal in vitro synthesis by monocytes in two cases with properdin deficiency type II due to distinct mutations. J Clin Immunol. 1998;18:272–282.
71. Cortes C, Ohtola JA, Saggu G, Ferreira VP. Local release of properdin in the cellular microenvironment: role in pattern recognition and amplification of the alternative pathway of complement. Front Immunol. 2012;3:412.
72. Schwaeble W, Dippold WG, Schafer MK, et al. Properdin, a positive regulator of complement activation, is expressed in human T cell lines and peripheral blood T cells. J Immunol. 1993;151:2521–2528.
73. Whaley K. Biosynthesis of the complement components and the regulatory proteins of the alternative complement pathway by human peripheral blood monocytes. J Exp Med. 1980;151:501–516.
74. Stover CM, Luckett JC, Echtenacher B, et al. Properdin plays a protective role in polymicrobial septic peritonitis. J Immunol. 2008;180:3313–3318.
75. Camous L, Roumenina L, Bigot S, et al. Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood. 2011;117:1340–1349.
76. Wirthmueller U, Dewald B, Thelen M, et al. Properdin, a positive regulator of complement activation, is released from secondary granules of stimulated peripheral blood neutrophils. J Immunol. 1997;158:4444–4451.
77. Kimura Y, Zhou L, Miwa T, Song WC. Genetic and therapeutic targeting of properdin in mice prevents complement-mediated tissue injury. J Clin Invest. 2010;120:3545–3554.
78. Ziegler JB, Rosen FS, Alper CA, Grupe W, Lepow IH. Metabolism of properdin in normal subjects and patients with renal disease. J Clin Invest. 1975;56:761–767.
79. Corvillo F, Bravo Garcia-Morato M, Nozal P, et al. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy. Clin Exp Immunol. 2016;184:118–125.
80. Pillemer L, Blum L, Lepow IH, Ross OA, Todd EW, Wardlaw AC. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science. 1954;120:279–285.
81. Chen Q, Manzke M, Hartmann A, et al. Complement factor H-related 5-hybrid proteins anchor properdin and activate complement at self-surfaces. J Am Soc Nephrol. 2016;27:1413–1425.
82. Cortes C, Ferreira VP, Pangburn MK. Native properdin binds to Chlamydia pneumoniae and promotes complement activation. Infect Immun. 2011;79:724–731.
83. Ferreira VP, Cortes C, Pangburn MK. Native polymeric forms of properdin selectively bind to targets and promote activation of the alternative pathway of complement. Immunobiology. 2010;215:932–940.
84. Gaarkeuken H, Siezenga MA, Zuidwijk K, et al. Complement activation by tubular cells is mediated by properdin binding. Am J Physiol Renal Physiol. 2008;295:F1397–F1403.
85. Hourcade DE. The role of properdin in the assembly of the alternative pathway C3 convertases of complement. J Biol Chem. 2006;281:2128–2132.
86. Kemper C, Mitchell LM, Zhang L, Hourcade DE. The complement protein properdin binds apoptotic T cells and promotes complement activation and phagocytosis. Proc Natl Acad Sci USA. 2008;105:9023–9028.
87. O'Flynn J, Dixon KO, Faber Krol MC, Daha MR, van Kooten C. Myeloperoxidase directs properdin-mediated complement activation. J Innate Immun. 2014;6:417–425.
88. O'Flynn J, van der Pol P, Dixon KO, Prohaszka Z, Daha MR, van Kooten C. Monomeric C-reactive protein inhibits renal cell-directed complement activation mediated by properdin. Am J Physiol Renal Physiol. 2016;310:F1308–F1316.
89. Spitzer D, Mitchell LM, Atkinson JP, Hourcade DK. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J Immunol. 2007;179:2600–2608.
90. Vuagnat BB, Mach J, Le Doussal JM. Activation of the alternative pathway of human complement by autologous cells expressing transmembrane recombinant properdin. Mol Immunol. 2000;37:467–478.
91. Xu W, Berger SP, Trouw LA, et al. Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathway complement activation. J Immunol. 2008;180:7613–7621.
92. Farries TC, Finch JT, Lachmann PJ, Harrison RA. Resolution and analysis of ‘native’ and ‘activated’ properdin. Biochem J. 1987;243:507–517.
93. Agarwal S, Ferreira VP, Cortes C, Pangburn MK, Rice PA, Ram S. An evaluation of the role of properdin in alternative pathway activation on Neisseria meningitidis and Neisseria gonorrhoeae. J Immunol. 2010;185:507–516.
94. Pauly D, Nagel BM, Reinders J, et al. A novel antibody against human properdin inhibits the alternative complement system and specifically detects properdin from blood samples. PLoS ONE. 2014;9:e96371.
95. Jelezarova E, Vogt A, Lutz HU. Interaction of C3b(2)–IgG complexes with complement proteins properdin, factor B and factor H: implications for amplification. Biochem J. 2000;349:217–223.
96. Agarwal S, Specht CA, Haibin H, et al. Linkage specificity and role of properdin in activation of the alternative complement pathway by fungal glycans. MBio. 2011;2:e00178–11.
97. Harboe M, Garred P, Lindstad JK, et al. The role of properdin in zymosan- and Escherichia coli-induced complement activation. J Immunol. 2012;189:2606–2613.
98. Eisenhardt SU, Habersberger J, Murphy A, et al. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ Res. 2009;105:128–137.
99. Zhou HF, Yan H, Stover CM, et al. Antibody directs properdin-dependent activation of the complement alternative pathway in a mouse model of abdominal aortic aneurysm. Proc Natl Acad Sci USA. 2012;109:E415–E422.
100. Yu H, Munoz EM, Edens RE, Linhardt RJ. Kinetic studies on the interactions of heparin and complement proteins using surface plasmon resonance. Biochim Biophys Acta. 2005;1726:168–176.
101. Zaferani A, Vives RR, van der Pol P, et al. Identification of tubular heparan sulfate as a docking platform for the alternative complement component properdin in proteinuric renal disease. J Biol Chem. 2011;286:5359–5367.
102. Zaferani A, Vives RR, van der Pol P, et al. Factor h and properdin recognize different epitopes on renal tubular epithelial heparan sulfate. J Biol Chem. 2012;287:31471–31481.
103. Hourcade DE, Akk AM, Mitchell LM, Zhou HF, Hauhart R, Pham CT. Anti-complement activity of the Ixodes scapularis salivary protein Salp20. Mol Immunol. 2016;69:62–69.
104. Wang Y, Miwa T, Ducka-Kokalari B, et al. Properdin contributes to allergic airway inflammation through local C3a generation. J Immunol. 2015;195:1171–1181.
105. Dimitrova P, Ivanovska N, Schwaeble W, Gyurkovska V, Stover C. The role of properdin in murine zymosan-induced arthritis. Mol Immunol. 2010;47:1458–1466.
106. Dimitrova P, Ivanovska N, Belenska L, Milanova V, Schwaeble W, Stover C. Abrogated RANKL expression in properdin-deficient mice is associated with better outcome from collagen-antibody-induced arthritis. Arthritis Res Ther. 2012;14:R173.
107. Ivanovska ND, Dimitrova PA, Luckett JC, El-Rachkidy Lonnen R, Schwaeble WJ, Stover CM. Properdin deficiency in murine models of nonseptic shock. J Immunol. 2008;180:6962–6969.
108. Kemper C, Atkinson JP, Hourcade DE. Properdin: emerging roles of a pattern-recognition molecule. Annu Rev Immunol. 2010;28:131–155.
109. Lesher AM, Nilsson B, Song WC. Properdin in complement activation and tissue injury. Mol Immunol. 2013;56:191–198.
110. Zarbock A, Polanowska-Grabowska RK, Ley K. Platelet-neutrophil-interactions: linking hemostasis and inflammation. Blood Rev. 2007;21:99–111.
111. Maugeri N, Brambilla M, Camera M, et al. Human polymorphonuclear leukocytes produce and express functional tissue factor upon stimulation. J Thromb Haemost. 2006;4:1323–1330.
112. Ritis K, Doumas M, Mastellos D, et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol. 2006;177:4794–4802.
113. Bussolino F, Sironi M, Bocchietto E, Mantovani A. Synthesis of platelet-activating factor by polymorphonuclear neutrophils stimulated with interleukin-8. J Biol Chem. 1992;267:14598–14603.
114. Chesney CM, Pifer DD, Byers LW, Muirhead EE. Effect of platelet-activating factor (PAF) on human platelets. Blood. 1982;59:582–585.
115. Mihara K, Ramachandran R, Renaux B, Saifeddine M, Hollenberg MD. Neutrophil elastase and proteinase-3 trigger G protein-biased signaling through proteinase-activated receptor-1 (PAR1). J Biol Chem. 2013;288:32979–32990.
116. Sambrano GR, Huang W, Faruqi T, Mahrus S, Craik C, Coughlin SR. Cathepsin G activates protease-activated receptor-4 in human platelets. J Biol Chem. 2000;275:6819–6823.
117. Cerletti C, Tamburrelli C, Izzi B, Gianfagna F, de Gaetano G. Platelet-leukocyte interactions in thrombosis. Thromb Res. 2012;129:263–266.
118. May AE, Langer H, Seizer P, Bigalke B, Lindemann S, Gawaz M. Platelet-leukocyte interactions in inflammation and atherothrombosis. Semin Thromb Hemost. 2007;33:123–127.
119. Totani L, Evangelista V. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler Thromb Vasc Biol. 2010;30:2357–2361.
120. Diacovo TG, Roth SJ, Buccola JM, Bainton DF, Springer TA. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Blood. 1996;88:146–157.
121. Evangelista V, Manarini S, Rotondo S, et al. Platelet/polymorphonuclear leukocyte interaction in dynamic conditions: evidence of adhesion cascade and cross talk between P-selectin and the beta 2 integrin CD11b/CD18. Blood. 1996;88:4183–4194.
122. Evangelista V, Manarini S, Sideri R, et al. Platelet/polymorphonuclear leukocyte interaction: P-selectin triggers protein-tyrosine phosphorylation-dependent CD11b/CD18 adhesion: role of PSGL-1 as a signaling molecule. Blood. 1999;93:876–885.
123. Weber C, Springer TA. Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factor. J Clin Invest. 1997;100:2085–2093.
124. Simon DI, Chen Z, Xu H, et al. Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med. 2000;192:193–204.
125. Chavakis T, Santoso S, Clemetson KJ, et al. High molecular weight kininogen regulates platelet-leukocyte interactions by bridging Mac-1 and glycoprotein Ib. J Biol Chem. 2003;278:45375–45381.
126. Diacovo TG, deFougerolles AR, Bainton DF, Springer TA. A functional integrin ligand on the surface of platelets: intercellular adhesion molecule-2. J Clin Invest. 1994;94:1243–1251.
127. Xie J, Li R, Kotovuori P, et al. Intercellular adhesion molecule-2 (CD102) binds to the leukocyte integrin CD11b/CD18 through the A domain. J Immunol. 1995;155:3619–3628.
128. Santoso S, Sachs UJ, Kroll H, et al. The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. J Exp Med. 2002;196:679–691.
129. Haselmayer P, Grosse-Hovest L, von Landenberg P, Schild H, Radsak MP. TREM-1 ligand expression on platelets enhances neutrophil activation. Blood. 2007;110:1029–1035.
130. Li G, Sanders JM, Bevard MH, et al. CD40 ligand promotes Mac-1 expression, leukocyte recruitment, and neointima formation after vascular injury. Am J Pathol. 2008;172:1141–1152.
131. Huo Y, Schober A, Forlow SB, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med. 2003;9:61–67.
132. Merhi Y, Provost P, Chauvet P, Theoret JF, Phillips ML, Latour JG. Selectin blockade reduces neutrophil interaction with platelets at the site of deep arterial injury by angioplasty in pigs. Arterioscler Thromb Vasc Biol. 1999;19:372–377.
133. Palabrica T, Lobb R, Furie BC, et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature. 1992;359:848–851.
134. Smyth SS, Reis ED, Zhang W, Fallon JT, Gordon RE, Coller BS. Beta(3)-integrin-deficient mice but not P-selectin-deficient mice develop intimal hyperplasia after vascular injury: correlation with leukocyte recruitment to adherent platelets 1 hour after injury. Circulation. 2001;103:2501–2507.
135. Ott I, Neumann FJ, Gawaz M, Schmitt M, Schomig A. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation. 1996;94:1239–1246.
136. Tekelioglu Y, Uzun H. Circulating platelet-leukocyte aggregates in patients with inflammatory bowel disease. J Chin Med Assoc. 2013;76:182–185.
137. O’sullivan BP, Linden MD, Frelinger AL, et al. Platelet activation in cystic fibrosis. Blood. 2005;105:4635–4641.
138. Elalamy I, Chakroun T, Gerotziafas GT, et al. Circulating platelet-leukocyte aggregates: a marker of microvascular injury in diabetic patients. Thromb Res. 2008;121:843–848.
139. Peerschke EI, Yin W, Ghebrehiwet B. Platelet mediated complement activation. Adv Exp Med Biol. 2008;632:81–91.
140. Peerschke EI, Yin W, Ghebrehiwet B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol. 2010;47:2170–2175.
141. Speth C, Rambach G, Wurzner R, et al. Complement and platelets: mutual interference in the immune network. Mol Immunol. 2015;67:108–118.
142. Peerschke EI, Yin W, Grigg SE, Ghebrehiwet B. Blood platelets activate the classical pathway of human complement. J Thromb Haemost. 2006;4:2035–2042.
143. Del Conde I, Cruz MA, Zhang H, Lopez JA, Afshar-Kharghan V. Platelet activation leads to activation and propagation of the complement system. J Exp Med. 2005;201:871–879.
144. Hamad OA, Nilsson PH, Lasaosa M, et al. Contribution of chondroitin sulfate A to the binding of complement proteins to activated platelets. PLoS ONE. 2010;5:e12889.
145. Hamad OA, Ekdahl KN, Nilsson PH, et al. Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets. J Thromb Haemost. 2008;6:1413–1421.
146. Hamad OA, Nilsson PH, Wouters D, Lambris JD, Ekdahl KN, Nilsson B. Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1. J Immunol. 2010;184:2686–2692.
147. Licht C, Pluthero FG, Li L, et al. Platelet-associated complement factor H in healthy persons and patients with atypical HUS. Blood. 2009;114:4538–4545.
148. Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol. 2005;23:821–852.
149. Maugeri N, Rovere-Querini P, Slavich M, et al. Early and transient release of leukocyte pentraxin 3 during acute myocardial infarction. J Immunol. 2011;187:970–979.
150. Jaillon S, Peri G, Delneste Y, et al. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med. 2007;204:793–804.
151. Lappegard KT, Fung M, Bergseth G, et al. Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation. Ann Thorac Surg. 2004;77:932–941.
152. Rinder CS, Rinder HM, Smith BR, et al. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest. 1995;96:1564–1572.
153. Rinder CS, Rinder HM, Smith MJ, et al. Selective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation. J Thorac Cardiovasc Surg. 1999;118:460–466.
154. Rinder CS, Rinder HM, Johnson K, et al. Role of C3 cleavage in monocyte activation during extracorporeal circulation. Circulation. 1999;100:553–558.
155. Rinder CS, Smith MJ, Rinder HM, et al. Leukocyte effects of C5a-receptor blockade during simulated extracorporeal circulation. Ann Thorac Surg. 2007;83:146–152.
156. Blatt AZ, Saggu G, Kulkarni KV, et al. Properdin-mediated C5a production enhances stable binding of platelets to granulocytes in human whole blood. J Immunol. 2016;196:4671–4680.
157. Hamad OA, Mitroulis I, Fromell K, et al. Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18. Thromb Haemost. 2015;114:1207–1217.
158. Ruef J, Kuehnl P, Meinertz T, Merten M. The complement factor properdin induces formation of platelet-leukocyte aggregates via leukocyte activation. Platelets. 2008;19:359–364.
159. Stahl AL, Sartz L, Karpman D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood. 2011;117:5503–5513.
160. Fung M, Loubser PG, Undar A, et al. Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits. J Thorac Cardiovasc Surg. 2001;122:113–122.
161. Gupta-Bansal R, Parent JB, Brunden KR. Inhibition of complement alternative pathway function with anti-properdin monoclonal antibodies. Mol Immunol. 2000;37:191–201.
162. Maugeri N, Baldini M, Ramirez GA, Rovere-Querini P, Manfredi AA. Platelet-leukocyte deregulated interactions foster sterile inflammation and tissue damage in immune-mediated vessel diseases. Thromb Res. 2012;129:267–273.
163. Semple JW, Italiano JE Jr, Freedman J. Platelets and the immune continuum. Nat Rev Immunol. 2011;11:264–274.
164. Ley K. The role of selectins in inflammation and disease. Trends Mol Med. 2003;9:263–268.
165. Rosetti F, Mayadas TN. The many faces of Mac-1 in autoimmune disease. Immunol Rev. 2016;269:175–193.
166. Xiao Z, Theroux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol. 2004;43:1982–1988.
167. Levi M, Eerenberg E, Kamphuisen PW. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost. 2011;9:1705–1712.
168. Ma YQ, Plow EF, Geng JG. P-selectin binding to P-selectin glycoprotein ligand-1 induces an intermediate state of alphaMbeta2 activation and acts cooperatively with extracellular stimuli to support maximal adhesion of human neutrophils. Blood. 2004;104:2549–2556.
169. Hoffman M, Blum A, Baruch R, Kaplan E, Benjamin M. Leukocytes and coronary heart disease. Atherosclerosis. 2004;172:1–6.
170. Carter AM. Complement activation: an emerging player in the pathogenesis of cardiovascular disease. Scientifica (Cairo). 2012;2012:402783.
171. Hansch GM, Gemsa D, Resch K. Induction of prostanoid synthesis in human platelets by the late complement components C5b-9 and channel forming antibiotic nystatin: inhibition of the reacylation of liberated arachidonic acid. J Immunol. 1985;135:1320–1324.
172. Polley MJ, Nachman R. The human complement system in thrombin-mediated platelet function. J Exp Med. 1978;147:1713–1726.
173. Polley MJ, Nachman RL. Human complement in thrombin-mediated platelet function: uptake of the C5b-9 complex. J Exp Med. 1979;150:633–645.
174. Wiedmer T, Sims PJ. Effect of complement proteins C5b-9 on blood platelets. Evidence for reversible depolarization of membrane potential. J Biol Chem. 1985;260:8014–8019.
175. Wiedmer T, Esmon CT, Sims PJ. On the mechanism by which complement proteins C5b-9 increase platelet prothrombinase activity. J Biol Chem. 1986;261:14587–14592.
176. Wiedmer T, Esmon CT, Sims PJ. Complement proteins C5b-9 stimulate procoagulant activity through platelet prothrombinase. Blood. 1986;68:875–880.
177. Zhou HF, Yan H, Bertram P, et al. Fibrinogen-specific antibody induces abdominal aortic aneurysm in mice through complement lectin pathway activation. Proc Natl Acad Sci USA. 2013;110:E4335–E4344.
178. Ross GD, Lambris JD. Identification of a C3bi-specific membrane complement receptor that is expressed on lymphocytes, monocytes, neutrophils, and erythrocytes. J Exp Med. 1982;155:96–110.
179. Wright SD, Rao PE, Van Voorhis WC, et al. Identification of the C3bi receptor of human monocytes and macrophages by using monoclonal antibodies. Proc Natl Acad Sci USA. 1983;80:5699–5703.
180. Huber-Lang M, Sarma JV, Zetoune FS, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med. 2006;12:682–687.
181. Amara U, Flierl MA, Rittirsch D, et al. Molecular intercommunication between the complement and coagulation systems. J Immunol. 2010;185:5628–5636.
182. Tyson KR, Elkins C, de Silva AM. A novel mechanism of complement inhibition unmasked by a tick salivary protein that binds to properdin. J Immunol. 2008;180:3964–3968.
183. Mathew S, Overturf GD. Complement and properidin deficiencies in meningococcal disease. Pediatr Infect Dis J. 2006;25:255–256.
184. Jain U, Midgen CA, Schwaeble WJ, Stover CM, Stadnyk AW. Properdin regulation of complement activation affects colitis in interleukin 10 gene-deficient mice. Inflamm Bowel Dis. 2015;21:1519–1528.
185. Jain U, Cao Q, Thomas NA, et al. Properdin provides protection from Citrobacter rodentium-induced intestinal inflammation in a C5a/IL-6-dependent manner. J Immunol. 2015;194:3414–3421.
186. Steiner T, Francescut L, Byrne S, et al. Protective role for properdin in progression of experimental murine atherosclerosis. PLoS ONE. 2014;9:e92404.
187. Alves-Filho JC, de Freitas A, Spiller F, Souto FO, Cunha FQ. The role of neutrophils in severe sepsis. Shock. 2008;30(Suppl 1):3–9.
188. Mihlan M, Stippa S, Jozsi M, Zipfel PF. Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H. Cell Death Differ. 2009;16:1630–1640.
189. Xu PC, Li ZY, Yang XW, Zhao MH, Chen M. Myeloperoxidase influences the complement regulatory function of modified C-reactive protein. Innate Immun. 2014;20:440–448.
190. Csincsi AI, Kopp A, Zoldi M, et al. Factor H-related protein 5 interacts with pentraxin 3 and the extracellular matrix and modulates complement activation. J Immunol. 2015;194:4963–4973.
191. Blackmore TK, Sadlon TA, Ward HM, Lublin DM, Gordon DL. Identification of a heparin binding domain in the seventh short consensus repeat of complement factor H. J Immunol. 1996;157:5422–5427.
192. Blackmore TK, Hellwage J, Sadlon TA, et al. Identification of the second heparin-binding domain in human complement factor H. J Immunol. 1998;160:3342–3348.
193. Clark SJ, Ridge LA, Herbert AP, et al. Tissue-specific host recognition by complement factor H is mediated by differential activities of its glycosaminoglycan-binding regions. J Immunol. 2013;190:2049–2057.
194. Khan S, Nan R, Gor J, Mulloy B, Perkins SJ. Bivalent and co-operative binding of complement factor H to heparan sulfate and heparin. Biochem J. 2012;444:417–428.
195. Pangburn MK, Atkinson MA, Meri S. Localization of the heparin-binding site on complement factor H. J Biol Chem. 1991;266:16847–16853.
196. Perkins SJ, Fung KW, Khan S. Molecular interactions between complement factor H and its heparin and heparan sulfate ligands. Front Immunol. 2014;5:126.
197. Prodinger WM, Hellwage J, Spruth M, Dierich MP, Zipfel PF. The C-terminus of factor H: monoclonal antibodies inhibit heparin binding and identify epitopes common to factor H and factor H-related proteins. Biochem J. 1998;331(Pt 1):41–47.
198. Schmidt CQ, Herbert AP, Kavanagh D, et al. A new map of glycosaminoglycan and C3b binding sites on factor H. J Immunol. 2008;181:2610–2619.
199. Herbert AP, Kavanagh D, Johansson C, et al. Structural and functional characterization of the product of disease-related factor H gene conversion. Biochemistry. 2012;51:1874–1884.
200. Pangburn MK, Rawal N, Cortes C, Alam MN, Ferreira VP, Atkinson MA. Polyanion-induced self-association of complement factor H. J Immunol. 2009;182:1061–1068.
201. Nagamachi S, Ohsawa I, Suzuki H, et al. Properdin has an ascendancy over factor H regulation in complement-mediated renal tubular damage. BMC Nephrol. 2014;15:82.
202. Barbour TD, Pickering MC, Terence Cook H. Dense deposit disease and C3 glomerulopathy. Semin Nephrol. 2013;33:493–507.
203. Fridkis-Hareli M, Storek M, Mazsaroff I, et al. Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood. 2011;118:4705–4713.
204. Nichols EM, Barbour TD, Pappworth IY, et al. An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy. Kidney Int. 2015;88:1314–1322.
205. Schmidt CQ, Bai H, Lin Z, et al. Rational engineering of a minimized immune inhibitor with unique triple-targeting properties. J Immunol. 2013;190:5712–5721.
206. Gulati S, Agarwal S, Vasudhev S, Rice PA, Ram S. Properdin is critical for antibody-dependent bactericidal activity against Neisseria gonorrhoeae that recruit C4b-binding protein. J Immunol. 2012;188:3416–3425.
207. Ali YM, Hayat A, Saeed BM, et al. Low-dose recombinant properdin provides substantial protection against Streptococcus pneumoniae and Neisseria meningitidis infection. Proc Natl Acad Sci USA. 2014;111:5301–5306.
208. Giuntini S, Pajon R, Ram S, Granoff DM. Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity. Infect Immun. 2015;83:1536–1545.
209. Schneider MC, Exley RM, Chan H, et al. Functional significance of factor H binding to Neisseria meningitidis. J Immunol. 2006;176:7566–7575.
210. Seib KL, Serruto D, Oriente F, et al. Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect Immun. 2009;77:292–299.
211. Alitalo A, Meri T, Lankinen H, et al. Complement inhibitor factor H binding to Lyme disease spirochetes is mediated by inducible expression of multiple plasmid-encoded outer surface protein E paralogs. J Immunol. 2002;169:3847–3853.
212. Biedzka-Sarek M, Jarva H, Hyytiainen H, Meri S, Skurnik M. Characterization of complement factor H binding to Yersinia enterocolitica serotype O:3. Infect Immun. 2008;76:4100–4109.
213. Horstmann RD, Sievertsen HJ, Knobloch J, Fischetti VA. Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proc Natl Acad Sci USA. 1988;85:1657–1661.